1. Name and Address of Reporting Person*  
   **Farrow Jeffrey S**  
   Last (Last) (First) (Middle)  
   C/O GLOBAL BLOOD THERAPEUTICS, INC.  
   181 OYSTER POINT BOULEVARD  
   SOUTH SAN FRANCISCO CA 94080  

2. Issuer Name and Ticker or Trading Symbol  
   **Global Blood Therapeutics, Inc. [GBT]**  

3. Date of Earliest Transaction (Month/Day/Year)  
   08/01/2020  

4. Individual or Joint/Group Filing (Check Applicable Line)  
   X Form filed by One Reporting Person  
   Form filed by More than One Reporting Person  

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  
   Director  
   10% Owner  
   Other (specify below)  
   Chief Financial Officer  

6. If Amendment, Date of Original Filed (Month/Day/Year)  
   08/01/2020  

7. Nature of Indirect Beneficial Ownership (Instr. 4)  

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/01/2020</td>
<td>M</td>
<td>12,082</td>
<td>A</td>
<td>(i) 15,130</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/01/2020</td>
<td>F</td>
<td>5,946</td>
<td>D</td>
<td>$67.48 9,184</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Beneficially Owned Following Reportedly Transferred (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Units</td>
<td>(i) 08/01/2020</td>
<td>M</td>
<td>3,062</td>
<td>(3) (3)</td>
<td>Common Stock 3,062</td>
<td>0.00 3,062</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>(i) 08/01/2020</td>
<td>M</td>
<td>2,875</td>
<td>(4) (4)</td>
<td>Common Stock 2,875</td>
<td>0.00 8,625</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>(i) 08/01/2020</td>
<td>M</td>
<td>3,125</td>
<td>(5) (5)</td>
<td>Common Stock 3,125</td>
<td>0.00 15,625</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>(i) 08/01/2020</td>
<td>M</td>
<td>3,020</td>
<td>(6) (6)</td>
<td>Common Stock 3,020</td>
<td>0.00 21,140</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:  
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.  
2. Represents number of shares of Issuer's Common Stock sold to satisfy the Reporting Person's tax obligations in connection with the vesting of 12,082 shares of Common Stock underlying the Reporting Person's RSUs.  
3. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.  
4. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.  
5. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.  
6. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.  

Remarks:  
/\ Tricia Suvari, as Attorney-in-Fact  
08/04/2020  
** Signature of Reporting Person Date  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).  
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.